NO20076245L - Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner - Google Patents

Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner

Info

Publication number
NO20076245L
NO20076245L NO20076245A NO20076245A NO20076245L NO 20076245 L NO20076245 L NO 20076245L NO 20076245 A NO20076245 A NO 20076245A NO 20076245 A NO20076245 A NO 20076245A NO 20076245 L NO20076245 L NO 20076245L
Authority
NO
Norway
Prior art keywords
tfpi
bacterial infections
treat severe
risk
severe bacterial
Prior art date
Application number
NO20076245A
Other languages
English (en)
Inventor
Stephen F Hardy
Yumin Dai
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20076245L publication Critical patent/NO20076245L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fremgangsmåter for profylaktisk eller terapeutisk behandling av en pasient som har risiko for å utvikle eller som har blitt diagnostisert som å ha en alvorlig bakteriell infeksjon omfattende administrering av en vevsfaktor pathway inhibitor (TFPI) eller en TFPI analog til pasienter som lider av eller har risiko for å utvikle denne tilstanden. Metodene involverer anvendelse av kontinuerlig intravenøs infusjon av TFPI eller en TFPI analog ved lave doseringer for å unngå uønskede bieffekter.
NO20076245A 2005-05-06 2007-12-04 Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner NO20076245L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67846505P 2005-05-06 2005-05-06
PCT/US2006/017956 WO2006122139A2 (en) 2005-05-06 2006-05-08 Use of tfpi to treat severe bacterial infections

Publications (1)

Publication Number Publication Date
NO20076245L true NO20076245L (no) 2007-12-06

Family

ID=37103012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076245A NO20076245L (no) 2005-05-06 2007-12-04 Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner

Country Status (16)

Country Link
US (1) US20090214506A1 (no)
EP (1) EP1877081A2 (no)
JP (1) JP2008540460A (no)
KR (1) KR20080017021A (no)
CN (1) CN101400365A (no)
AU (1) AU2006244053A1 (no)
BR (1) BRPI0611049A2 (no)
CA (1) CA2607293A1 (no)
IL (1) IL187111A0 (no)
MA (1) MA29489B1 (no)
MX (1) MX2007013876A (no)
NO (1) NO20076245L (no)
RU (1) RU2007145202A (no)
TN (1) TNSN07413A1 (no)
WO (1) WO2006122139A2 (no)
ZA (1) ZA200709520B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN105473619B (zh) 2013-07-19 2020-12-15 诺和诺德股份有限公司 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
CN105777876B (zh) * 2016-05-26 2020-02-11 青岛农业大学 一种抗菌肽tc38及其应用
CN105777875B (zh) * 2016-05-26 2020-02-11 青岛农业大学 一种抗菌肽cstc24及其应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11572295B1 (en) * 2019-06-11 2023-02-07 Swamp Fox Innovations, LLC Compositions and methods for reduction of free chlorine and related odor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0500472A2 (hu) * 2001-10-15 2005-08-29 Chiron Corporation Szepszis kezelése kis dózisú szöveti faktor bioszintézis inhibitor (TFPI) beadásával
WO2005019265A1 (en) * 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs

Also Published As

Publication number Publication date
RU2007145202A (ru) 2009-06-20
BRPI0611049A2 (pt) 2010-08-10
US20090214506A1 (en) 2009-08-27
JP2008540460A (ja) 2008-11-20
MX2007013876A (es) 2008-04-02
AU2006244053A1 (en) 2006-11-16
TNSN07413A1 (en) 2009-03-17
KR20080017021A (ko) 2008-02-25
WO2006122139A2 (en) 2006-11-16
CA2607293A1 (en) 2006-11-16
EP1877081A2 (en) 2008-01-16
WO2006122139A3 (en) 2007-04-26
ZA200709520B (en) 2008-11-26
MA29489B1 (fr) 2008-05-02
IL187111A0 (en) 2008-02-09
CN101400365A (zh) 2009-04-01

Similar Documents

Publication Publication Date Title
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2009021521A3 (en) Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
EA200971053A1 (ru) Способы лечения кожных язв
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
NO20064964L (no) Behandling av svekket respiratorisk funksjon
WO2003032904A3 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
MXPA05012392A (es) Tratamientos de ansiedad con ziprasidona.
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
RU2007112409A (ru) Одновременный прием тигициклина и дигоксина
KR20120128644A (ko) 질환의 치료에 사용하기 위한 화합물
NO20064674L (no) Behandling av alvorlig lungebetennelse ervervet utenfor sykehus ved administrering av vevsfaktor pathway inhibitor
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
NO20075898L (no) Behandling av samfunnsvervet lungebetennelse ved administrering av vevsfaktor pathway inhibitor (TFPI)
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application